1682.6000 10.60 (0.63%)
NSE Jul 14, 2025 15:31 PM
Volume: 1.3M
 

Centrum Broking
We maintain our Hold rating on Sun Pharma (SPIL) with TP of Rs580 (earlier Rs580) based on 26x March'20E EPS of Rs22.4. SPIL has developed a strong pipeline of specialty products for the US. It has received US FDA approval for Xelpros used in the treatment of glaucoma and ocular hypertension. We expect $22mn (Rs1.58bn) revenues from Xelpros in FY20. Key upside risks to our assumption include higher revenues from the US market and key downside risk includes regulatory risks for...
Number of FII/FPI investors increased from 1310 to 1351 in Mar 2025 qtr.
More from Sun Pharmaceutical Industries Ltd.
Recommended